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Angioplaaty: Clinical and Economic Implications
W.S. Weintraub, S.J. Boccuzzi, Y. Shen, Z. Ghszzal, J.S. Douglas, Jr.,
D.C. Morris, S.B. King Ill. Emory University Atlanta, GA, USA
It is the purpose of this study to identify patients at high risk of acute close or
other events after PTCAwho could benefit from GPllbllla blockade, thrombin
inhibition or other therapy to inhibit thrombus formation. In this study 5946
patienta had procedures to 7591 sitaa between 1/1/93 and 12/31/95. There
were 98(l.23%) episodes of acute closure inthelaboratoty. Hospitalmortality
was 0.6Y0without acute closure and 6.9% with acute closure. There were
only trends for clinical variables predicting acute closure: hypertension (p
= 0.062), and ejection fraction (p = 0.094). Several lesion characteristiee
predicted acute closure including length (p= 0.031), diameter stermsis pre-
proeedure (p = 0.015), ulcer (p = 0.036), diffuse disease (p = 0.073), calcium
(p = 0.0005), branch point (p = 0.005) and thrombus (p < 0.00Q1). The
multivariate correlates of acute closure were leaion length (OR 1.021 par
mm), thrombus (OR 1.955),Calcium(OR 2.241) and branch point (OR 1.790).
59% of patients had < 1% probability of acute closure. Similar models were
built foreomposite endpoints. There were 211 events of the composite acute
cloeure in the Iaksxatory, death or myoeardial infarction. The multivariate
predictors were lesion length (OR 1.028 par mm), thrombus (OR 2.73) and
calcium (OR 2.37). The 150 patients with the composite endpoint had a
29% chance of requiring CABG vs 1.7% in 5654 without the eompoeite
endpoint. Hospital cost in the composite endpoint patients was $24,789 vs
$10,202 without the composite endpoint. A similar model included CABG in
the composite endpoint with similar correlates. This permitted the creation of
a high risk profile of 24% of sites with a risk of=- 3% and which included 469!.
of events. Inhibition of thrombus ean be targeted to a high riak population
using simple anatomic criteria, permitting rational and cost effective patient
selection.
m108210 What Predicts Contrast Nephropathy AfterCoronary Intervention? Inaighte from the IMPACT
II Trial
M.C. Thel, C.J. Davideon, F.V.Aguirre, S.L. Peek, J.E. Tcheng, A.M. Lincdf,
E.J. Topol, R.M. Califf for the IMPACT II Investigators. Duke University
Medical Centec Durham, NC, USA
To determine the factors associated with ecmtrestnephropathy (CN) after
percutaneous Ooronav intervention, we analyzed the 4010 patients enrolled
in IMPACT-II. CN was defined as an increase in serum creatinine (Cr) after
contrast administration by z 0.5 m~dL. The median baseline Cr was 1
(0.9, 1.2); the median change in Cr following intervention was O(-0.1, 0.1).
Overall, 88 patiente (2%) developed CN and 9 patients required dialysis.
The variables included in the multiple l~istic regression model and their
associations are listed in the table:
Variable x’ p
Baseline Cr 15.s4 0.0003
Age 8.50 0.0035
Ejectionfraction 5.30 0.0213
Contrestvolume 4.25 0.0393
Diabstes meilitus(2 df) 4.58 0.1015
rXntrastclass (ioniolnonionicham) 0.66 0.4148
Calcium arrtagonistpre-prwedure 0.02 0.8751
Hypertension 0.01 0.9147
Total 33.96 0,0001
Baseline renal insufficiency is the most significant risk factor for CN
after coronary intervention. Diabetes, hypertension, contrast class, and pre-
treatment with calcium antagonists were not predictive.
D108211 Differential Effacta of Argatroban and Heparin on
Hemochron and HemoTec Activated Clotting
Timaa in Patients Undergoing Coronary
Intervantional Procedures
M.J. Hursting, J.-C. Becker, B.E. Lewis, O. Iqbal, J.M. Walenga,
J.J. Ferguson. TexasBiotechnology Corp., and The TexasHaart Institute,
Houston, TX, USA
Anticoagulation during coronary interventional procedures (1P)is often mon-
itored using the whole blcsxl activated clotting time (ACT). We sought to
establish the differential effects of the direct thrombin inhibitor argatroban,
compared to heparin, on Hemoehron ACTS using celite activator versus
HemoTec ACTSusing kaolin activator in patients undergoing 1P.Paired, si-
multaneous ACT values were determined using both methods for (a) 75
specimens from nine patients undergoing IP with argatroban anticoagula-
tion, and (b) 36 spaeimens from five patients undergoing IP with heparin
anticoagulation. By least squares regression analyses (Fig. 1), paired ACT
values were strongly correlated (r ? 0.86) for both druga. However, arga-
troban prolonged HemoTec and Hemochron ACTS equally (slope = 0.98
+ 0.06), whereas heparin prolonged HemoTae ACTS less than Hemoehron
ACTS(slope = 0.68+ 0.07; shown in Fig. 1).
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Cone/usiorrs:Argatrobanandheparin exert dissimilar effaetson Hemochron
and HemoTecAC.TSin patients undergoing 1P.Caution should thus be taken
if applying target ACT values recommended for adequate hepannization to
interventional procedures using argatroban.
\ 1082-12 I AdditionaiHeparin hIcraaseathe ACT and
Reducas the Likelihood of Abrupt Closura During
PTCA
J.A. Bittl, A.P. Selwyn, R.N. Piana, W.H. Ahmed. Brigham & Women’s
Hospital, Boston, MA, USA
The Hirulog Angioplasty Study allowed examination of the relation betwean
the risk of abrupt vessel closure (AVC) and activated clotting timea (ACT)
during PTCA. In uneventful, brief procedures the risk of AVC was inversely
related to the ACT achieved on heparin (OR= –1 .6’%0per IO-SW increase in
ACT [95% Cl = –3.4Y0,0.2%], P= 0.08, see below). The effect of additional
heparin given during complicated, prolonged procedures has not been de-
fined. Again, the risk of AVC was inversely related to the maximal ACT (OH
= –1,1% [95% Cl –2.3%, –0.1%], P= 0.04):
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Abrupt vessel closure is an adverse event that is strongly related to bad
outcomes after PTCA. This study suggests that increasing the ACT with
additional heparin reduces the risk of abrupt closure even in prolongad and
complicated procedures.
Wednesday, March 19, 1997, 3:00 p.m.–5:OOpm,
Anaheim Convention Center, Hall E
Presentation Hour: 4:00 p.m.–5:OOp.m.
I 1083-116I AntiorridantaAttenuate NOrepinephrine-hIdLIced
Cardiac Sympathetic Nerve Dysfunction
N.K. Rounds, S.Y. Felten, CS. Liang. University of Rochester Medica/
Cantec Rochestec N% USA
Cardiac norepinephrine (NE) uptake activity and noradrenergic nerve pro-
files are reduced in animals with congestive heart failure (CHF) or chronic
NE infusion. We hypothesized this sympathetic dysfunction is caused by
bcal accumulation of NE-derived oxidative products. To determine whether
these changes could be prevented by antioxidant, we administered vita-
mins (vits) A, C, and E or placebos to ferrets treated with NE (1.3 mgld)
or control pellats for 4 weeks (n = 6-10 per group). NE infusion caused
a 4-5 fold increase in plasma NE, but had no significant effect on bleed
pressure or heart rate. We measured plasma NE (rig/ml) and left ventricular
(LV) NE uptake activity (fmol/mg/15 rein). LV sympathetic nerve terminal Dro-
